Molbio Diagnostics is set for a significant stock market debut following a robust IPO subscription of 70 times. With a promising grey market premium suggesting a 19.3% rise over its issue price, investors are eagerly awaiting Monday's listing on the NSE and BSE.
Molbio Diagnostics is set for a significant stock market debut following a robust IPO subscription of 70 times. With a promising grey market premium suggesting a 19.3% rise over its issue price, investors are eagerly awaiting Monday's listing on the NSE and BSE.
<iframe src="https://hindustansphere.com/embed/cluster/f19a37ba119026e2e8be4c83680ae3724f170628" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Molbio Diagnostics IPO listing in focus: GMP signals nearly 20% listing pop ahead of debut on Monday"></iframe>
